超声联合CT检查在肝恶性肿瘤射频消融治疗中的应用价值探讨*

doi:10.3969/j.issn.1672-5069.2020.04.034

摘要/Abstract

摘要： 目的探讨超声联合计算机断层扫描(CT)引导下射频消融(RFA)治疗肝恶性肿瘤患者的疗效。方法 2017年3月～2019年1月我院收治的肝恶性肿瘤患者96例,均接受射频消融治疗,其中46例在超声引导下,50例在超声联合CT引导下行RFA治疗。在术后3个月复查MRI,评估疗效。结果在RFA治疗3个月后,超声联合CT引导组总有效率为94.0%,显著高于超声引导组的80.4%(P<0.05);在RFA治疗后两组并发症发生率分别为4.0%和13.0%,差异无统计学意义(P>0.05);治疗后,超声联合CT引导组血清肌酐和AFP水平分别为(71.5±7.2) mol/L和(30.4±5.7) g/L,与超声引导组的(70.6±7.3) mol/L和(31.8±5.6) g/L比,差异无统计学意义(P>0.05)。结论在行RFA治疗肝恶性肿瘤患者时,采取超声联合CT检查引导可保证穿刺更精确,消融效果更好,且并发症发生率低,具有很大的临床应用价值。

关键词: 肝恶性肿瘤, 射频消融, 超声引导, 计算机断层扫描引导, 治疗

Abstract: Objective The aim of this study was investigate the short-term efficacy of radiofrequency ablation (RFA) in patients with hepatic malignant tumors under ultrasound (US)- or US and CT combination-guidance. Methods A retrospective study was conducted on 96 patients with hepatic malignant tumors who underwent RFA under US and CT-guidance (group A) or US-guidance (group B) in our hospital from March 2017 through January 2019. All patients received RFA therapy, and were followed-up for three months. Results At the end of three months after RFA treatment, the total response rate in group A was significantly higher than that in group B (94.0% vs. 80.4%, P<0.05); after RFA treatment, there was no significant difference in incidence of complications between the two groups (4.0% vs. 13.0%, P>0.05); there were no significant differences as respect to serum creatinine and AFP levels between the two groups [(71.5±7.2) μmol/L vs. (70.6±7.3) μmol/L and (30.4±5.7) μg/L vs. (31.8±5.6) μg/L, respectively, P>0.05]. Conclusion The short-term efficacy of RFA guided by ultrasound and CT combination in the treatment of patients with hepatic malignant tumors is better as compared with routine ultrasound guidance, with low postoperative incidence of complications, which might be due to precise guidance and total ablation.

Key words: Liver malignant tumor, Ultrasound, Computed tomography, Radiofrequency ablation, Therapy

郑雪, 宣之东, 王玉, 张丽静. 超声联合CT检查在肝恶性肿瘤射频消融治疗中的应用价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(4): 589-592.

Zheng Xue, Xuan Zhidong, Wang Yu, et al. Short-term efficacy ofradiofrequency ablation in patients with hepatic malignant tumors under ultrasound- or US and CT combination-guidance[J]. Journal of Practical Hepatology, 2020, 23(4): 589-592.

参考文献

[1]Ya L, Zhicheng L, Yi S, et al. AMOT is required for YAP function in high glucose induced liver malignancy. Biochem Biophy Res Commun, 2017, 495(1):1555.
[2]Mirko D’O, Nicolò C, Andrea R, et al. Unenhanced magnetic resonance imaging immediately after radiofrequency ablation of liver malignancy: preliminary results. Abdom Radiol, 2017, 43(1):5-7.
[3]马履翔, 张雪松. 超声引导下经皮射频消融治疗小肝癌患者疗效及预后分析. 实用肝脏病杂志, 2019, 22(1):130-133.
[4]Bo Y, Yuwei L. A comparative study of laparoscopic microwave ablation with laparoscopic radiofrequency ablation for colorectal liver metastasis. J BUON, 2017, 22(3):667-672.
[5]中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版). 中华消化外科杂志, 2017, 16(7):635-647.
[6]Tan SY, Visvanathan S, Abu Hassan R, et al. Autophagic degradation of misfolded nuclear receptor co-repressor (NCoR) is linked to the growth of tumor cells in HBX positive hepatocellular carcinoma (HCC). Front Oncol, 2019,9:1335.
[7]Lu B, Zhu L, Wang X, et al. Effects of radiofrequency ablation combined with transarterial chemoembolization and antiviral therapy on the prognosis and quality of life in primary chronic HBV-related liver cancer. J BUON, 2019, 24(5):1979-1984.
[8]Zhang H, Sun Y, Xu H, et al. Endpoint of embolization: A study of transarterial chemoembolization in patients with large hepatocellular carcinoma.
J BUON, 2019,24(5):1970-1978.
[9]Ranjpour M, Wajid S, Jain SK.. Elevated expression of cytosolic phospholipase A2 delta is associated with lipid metabolism dysregulation during hepatocellular carcinoma progression.Cell J, 2020,22(1):17-22.
[10]Bettinger D, Pinato DJ, Schultheiss M, et al. Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: A propensity score analysis. Liver Cancer, 2019,8(4):281-294.
[11]Kudo M, Ueshima K, Osaki Y, et al. B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: A prospective multicenter randomized controlled trial. Liver Cancer, 2019,8(4): 271-280.
[12]韩玥, 郝玉芝, 蔡建强,等. 经皮射频消融治疗肝脏恶性肿瘤中辅助注入等渗盐水技术的应用价值.中华肝脏病杂志, 2012, 20(4):266-269.
[13]Yoon I S, Shin J H, Han K, et al. Ultrasound-guided intraoperative radiofrequency ablation and surgical resection for liver metastasis from malignant gastrointestinal stromal tumors. Korean J Radiol,2018,19(1):54-62.
[14]Rika Y, Akinori D, Tomoaki Y, et al. Prediction of the ablated area prior to radiofrequency ablation for liver tumor under CT guidance. Minim invas Ther Allied Technol, 2017, 27(1):1-5.
[15]Xiaotong S, Jutong S, Hua H, et al. Hsa_circ_0070269 inhibits hepatocellular carcinoma progression through modulating miR-182/NPTX1 axis. Biomed Pharmacother, 2019,120:109497
[16]Kumar P, Agarwal A, Singh AK, et al. Antineoplastic properties of zafirlukast against hepatocellular carcinoma via activation of mitochondrial mediated apoptosis. Regul Toxicol Pharmacol, 2019,109:104489.
[17]周进学,展翔宇,李庆军,等.人工腹水辅助超声引导邻近胃肠道肝脏肿瘤射频消融术.中华肝胆外科杂志,2018,24(1):9-12.
[18]Du X, Chen D, Lin Z, et al. Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: a retrospective, multicenter study.J BUON, 2019,24(5):1956-1963.
[19]Han Y, Shao N, Xi X, et al. Use of microwave ablation in the treatment of patients with multiple primary malignant tumors. Thorac Cancer,2017, 8(4):365-371.
[20]Lee D H, Lee J M. Recent advances in the image-guided tumor ablation of liver malignancies:radiofrequency ablation with multiple eElectrodes, real-time multimodality fusion imaging, and new energy sources. Korean J Radiol, 2018, 19(4):545-559.
[21]Ciprian C, Vlad R, Elena C, et al. Immediate and long-term results of radiofrequency ablation for colorectal liver metastases. Anticancer Res, 2017, 37(11):6489-6494.
[22]梅丽丽, 聂磊, 曾书娥. 超声造影时间-强度曲线在肝脏恶性肿瘤射频消融中的应用价值.中华诊断学电子杂志, 2018, 6(4): 226-231.

超声联合CT检查在肝恶性肿瘤射频消融治疗中的应用价值探讨^*

Short-term efficacy ofradiofrequency ablation in patients with hepatic malignant tumors under ultrasound- or US and CT combination-guidance

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	卓丽, 许敏, 邓浩辉. 阿舒瑞韦联合达拉他韦治疗慢性丙型肝炎患者初步疗效及其病毒准种变化和耐药变异特征分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 504-507.
[2]	黄丽华, 杨正兵, 谭礼让. 熊去氧胆酸联合非诺贝特治疗PBC患者血清TGF-β、IFN-γ和IL-10水平变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 520-523.
[3]	齐敬聪, 邢文静, 杜洋, 高辰玮. 熊去氧胆酸联合微生态制剂治疗原发性胆汁性胆管炎患者对肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 524-527.
[4]	侯光华, 胡启江, 徐美华, 朱绍咏, 黄波. 多烯磷脂酰胆碱联合二甲双胍和非诺贝特治疗NAFLD患者血清Pygo2和血脂水平变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 528-531.
[5]	周娜, 蒋磊, 吴冰冰. 阿托伐他汀治疗NAFLD患者对肝脂肪变和外周血Treg/Th17细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 532-535.
[6]	陈曦, 陈照林, 董静, 宋海燕, 刘波, 张骏飞, 陈从新. 脐带间充质干细胞联合双重血浆分子吸附治疗慢加急性肝衰竭患者临床效果初步观察[J]. 实用肝脏病杂志, 2020, 23(4): 544-547.
[7]	张静, 周新民. 应用重组人血小板生成素减少肝硬化患者术前血小板输注疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 552-555.
[8]	陈照林, 董静, 宋海燕, 刘波, 张骏飞. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者临床研究[J]. 实用肝脏病杂志, 2020, 23(4): 556-559.
[9]	全亚宁, 商晓杰, 孟璇, 高榆秀. 实时超声造影和融合影像导航下微波消融与手术治疗小肝癌患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(4): 581-584.
[10]	魏倩, 王艳, 游岚岚, 苟博. 超声引导下微波消融治疗早期泡型肝包虫病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 593-596.
[11]	艾国,王鸣,朱纪玲,邢铭友. 应用N-乙酰半胱氨酸治疗慢性乙型肝炎重度患者临床疗效初步研究[J]. 实用肝脏病杂志, 2020, 23(3): 336-339.
[12]	方利娟,吴雄飞. 恩替卡韦治疗乙型肝炎病毒携带者合并肺结核患者临床疗效分析[J]. 实用肝脏病杂志, 2020, 23(3): 340-343.
[13]	符垂师,张杰伟. α干扰素联合利巴韦林治疗儿童丙型肝炎患者病毒学应答率分析[J]. 实用肝脏病杂志, 2020, 23(3): 344-347.
[14]	杜颖,姜志红,吴雅玲. 雷公藤多甙联合异甘草酸镁治疗儿童自身免疫性肝炎疗效及其对血清IL-17和CXCL10水平的影响[J]. 实用肝脏病杂志, 2020, 23(3): 348-351.
[15]	沈金勇,郭翔云,周辉,罗乐. Hp根治治疗对非酒精性脂肪性肝病患者血清细胞因子和血脂水平的影响[J]. 实用肝脏病杂志, 2020, 23(3): 364-367.